title: A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
abstract: Infantile spasms are seizures manifesting within a spectrum of epileptic encephalopathies of infancy that often lead to cognitive impairment. Their current therapies, including adrenocorticotropic hormone (ACTH), high dose steroids, or vigabatrin, are not always effective and may be associated with serious side effects. Overactivation of the TORC1 complex of the mTOR pathway is implicated in the pathogenesis of certain genetic and acquired disorders that are linked with infantile spasms, like tuberous sclerosis. Here, we tested the therapeutic potential of rapamycin, a TORC1 inhibitor, as a potential treatment for infantile spasms in the multiple-hit rat model of ACTH-refractory symptomatic infantile spasms, which is not linked to tuberous sclerosis. Rapamycin or vehicle was given after spasms appeared. Their effects on spasms, other seizures, performance in Barnes maze, and expression of the phosphorylated S6 ribosomal protein (pS6: a TORC1 target) in the cortex, using immunofluorescence, were compared. Rapamycin suppressed spasms dose-dependently and improved visuospatial learning, although it did not reduce the frequency of other emerging seizures. High-dose pulse rapamycin effected acute and sustained suppression of spasms and improved cognitive outcome, without significant side effects. Therapeutically effective rapamycin doses normalized the pS6 expression, which was increased in perilesional cortical regions of pups with spasms. These findings support that pathological overactivation of TORC1 may be implicated in the pathogenesis of infantile spasms, including those that are not linked to tuberous sclerosis. Furthermore, a high-dose, pulse rapamycin treatment is a promising, well tolerated and disease-modifying new therapy for infantile spasms, including those refractory to ACTH.
authors.affiliation: Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx NY 10461, USA.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Raffo
authors.forename: Antonietta
authors.initials: A
authors.lastname: Coppola
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ono
authors.forename: Stephen W
authors.initials: SW
authors.lastname: Briggs
authors.forename: Aristea S
authors.initials: AS
authors.lastname: Galanopoulou
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000494:pharmacology* / Q000627:therapeutic use; D013036:Spasms, Infantile / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology
chemical_list: C519510:Crtc1 protein, rat; D014157:Transcription Factors; D020123:Sirolimus